Physician profile
Ned Mehlman
NPI 1093712283
$599.51
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $89.59 · 2021: $98.57 · 2022: $202.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $131.83 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $126.57 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $117.04 | 2019-2021 | |
| Amgen INC. | $99.66 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.12 | 2019 | |
| Pfizer INC. | $17.46 | 2022 | |
| Merck Sharp & Dohme LLC | $15.31 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ned Mehlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.